Cannabics Pharmaceuticals Inc., a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has completed its preclinical development of a novel formulation containing cannabinoids which have demonstrated anti-tumor properties in studies held at the company’s High Throughput Screening (HTS) research facility in Israel, which were focused on gastrointestinal cancers.
The company plans to examine the clinical safety and efficacy of the novel formulation which contains high concentrations of the cannabinoids CBDV and CBGA in a proprietary formulation...
Read the full text on the site GMPnews.Net